Concepedia
Statistics
Publications
9
Citations
965
H-Index
Active since
2022
Affiliations
The Netherlands Cancer Institute(Current)
OLVG
Oncode Institute
Spaarne Ziekenhuis
Radboud University Nijmegen
Y.L. Verschoor is an author at The Netherlands Cancer Institute specializing in cancer immunotherapy, oncology, and immunotherapy.
Publications per year
2022–2025
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
Myriam Chalabi, Y.L. Verschoor, Pedro Batista Tan et al. · New England Journal of Medicine · 2024 · 392 citations · Full text
Medicine, Immunology, Oncology +12
LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Myriam Chalabi, Y.L. Verschoor, J. van den Berg et al. · Annals of Oncology · 2022 · 191 citations · Full text
Life Sciences, Immunology, Oncology +16
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Y.L. Verschoor, Joris van de Haar, José G. van den Berg et al. · Nature Medicine · 2024 · 107 citations · Full text
Medicine, Oncology, Pharmacology +17
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
P.G.M. de Gooyer, Y.L. Verschoor, L.D.W. van den Dungen et al. · Nature Medicine · 2024 · 102 citations · Full text
Medicine, Immunology, Oncology +16
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
Y.L. Verschoor, José van den Berg, Geerard L. Beets et al. · Journal of Clinical Oncology · 2022 · 95 citations
1–5 of 9